According to the Department of Health and Social Care (DHSC), the commitments will enable patients t...
Read moreConsequently, paybacks from pharmaceutical manufacturers of around €1 billion will be due from pha...
Read moreThe draft final guidance reverses previous guidance issued in November 2021 rejecting the drug for r...
Read morePatients in England will be the first in Europe to have access to Takeda’s Exkivity (mobocertinib)...
Read morePRIME medicines include CAR T-cell therapies, one-time potentially curative gene therapies, rare can...
Read moreThe DHSC is proposing to increase the statutory scheme payment percentage for 2022 from 10.9% to 14....
Read moreThe proposals are set out in the draft Statutory Health Insurance Financial Stabilisation Bill which...
Read moreBased on a recent decision by the Interministerial Commission on Medicines Prices offering a price l...
Read moreTwo NICE teams (NICE International and the Science Policy and Research Programme) will act as key en...
Read moreThe study looks at the direct, indirect and mortality-related costs of 24 rare diseases across five ...
Read more